HIGHLIGHTS
- who: PDGFRA D and collaborators from the Department of Gastrointestinal Oncology, Laboratory of Carcinogenesis and Translational Research of Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, People`s Republic of China have published the paper: Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic GIST: A Phase I/II, Open-Label, Multicenter Study, in the Journal: (JOURNAL)
- what: The authors report the efficacy of avapritinib in patients with PDGFRA D842V mutations regardless of prior lines of treatment, and in patients without PDGFRA D842V mutations receiving fourth- or later . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.